Loading filters...
50 results(scroll for more)
GeneralAll Stages2026
ZW191, a FRα-targeted topoisomerase 1 inhibitor ADC with a differentiated antitumor efficacy and tolerability profile.
Lawn S et al. Clin Cancer Res. 2026
GeneralAdvanced/Recurrent2026
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trial.
Beinse G et al. Int J Gynecol Cancer. 2026
MSI-H/dMMRAll Stages2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
Powell MA et al. Gynecol Oncol. 2026
ImmunotherapyAdvanced/Recurrent2026
Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer.
Patterson B et al. Gynecol Oncol. 2026
ImmunotherapyAll Stages2026
Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study.
Lim S et al. Gynecol Oncol. 2026
MSI-H/dMMRAll Stages2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.
Ngoi NYL et al. Lancet Oncol. 2026
Hormone therapyAll Stages2026
The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer.
Kailasam A et al. Gynecol Oncol. 2026
GeneralAdvanced/Recurrent2026
A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).
Eskander RN et al. Int J Gynecol Cancer. 2026
MSI-H/dMMRAll Stages2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.
Rubinstein MM et al. Clin Cancer Res. 2026
ImmunotherapyAdvanced/Recurrent2026
A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma.
Turner KA et al. Gynecol Oncol. 2026
MSI-H/dMMRAdvanced/Recurrent2026
Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).
Kim SI et al. J Gynecol Oncol. 2026
ImmunotherapyAll Stages2026
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.
Santin AD et al. Clin Cancer Res. 2026
GeneralEarly (I-II)2026
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
Kuroki LM et al. Gynecol Oncol. 2026
Hormone therapyEarly (I-II)2026
Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities.
Podder V et al. Clin Cancer Res. 2026
Hormone therapyAll Stages2026
Androgen receptor as a therapeutic target in endometrial cancer: a narrative review.
Erfani H et al. Int J Gynecol Cancer. 2026
MSI-H/dMMRAdvanced/Recurrent2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial.
Marth C et al. Int J Gynecol Cancer. 2026
HER2+All Stages2026
Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.
Palmieri L et al. Gynecol Oncol. 2026
ImmunotherapyAdvanced/Recurrent2026
Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO- E/GOG-3041/ENGOT-EN10 trial.
Westin SN et al. Gynecol Oncol. 2026
GeneralEarly (I-II)2026
Demographics, clinicopathological features, and survival outcomes of women with endometrial neuroendocrine tumors.
Bou Zerdan M et al. Gynecol Oncol. 2026
HER2+All Stages2026
AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
Tankou J et al. Gynecol Oncol. 2026
MSI-H/dMMRAll Stages2026
Gynecologic cancers in 2025: a year in review.
Arenhardt MP et al. Int J Gynecol Cancer. 2026
MSI-H/dMMRAdvanced/Recurrent2025
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.
Zhu Y et al. J Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome.
Yang X et al. J Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Prevalence of and risk factors for endometrial polyps among asymptomatic postmenopausal women with uterovaginal prolapse.
Weigel GM et al. Am J Obstet Gynecol. 2025
HER2+Advanced/Recurrent2025
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.
van Dijk D et al. J Clin Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
Coleman RL et al. Gynecol Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Ta QD et al. Gynecol Oncol. 2025
MSI-H/dMMREarly (I-II)2025
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors.
Slomovitz BM et al. J Clin Oncol. 2025
GeneralAdvanced/Recurrent2025
A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors.
Shin SJ et al. Clin Cancer Res. 2025
GeneralEarly (I-II)2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial.
Post CCB et al. Lancet Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy.
Podder V et al. Int J Gynecol Cancer. 2025
GeneralAll Stages2025
Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
Tyrakis PA et al. Br J Cancer. 2025
MSI-H/dMMREarly (I-II)2025
Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma.
Obermair A et al. Int J Gynecol Cancer. 2025
GeneralAdvanced/Recurrent2025
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
Lindemann K et al. Gynecol Oncol. 2025
GeneralAll Stages2025
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Matei DE et al. J Clin Oncol. 2025
MSI-H/dMMRAdvanced/Recurrent2025
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Eskander RN et al. Nat Med. 2025
MSI-H/dMMRAll Stages2025
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
Ettorre VM et al. Gynecol Oncol. 2025
MSI-H/dMMRAll Stages2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
O'Malley DM et al. Gynecol Oncol. 2025
MSI-H/dMMRAll Stages2025
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Powell MA et al. Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Characteristics of endometrial cancer progressed to extrauterine lesions following fertility preserving medroxyprogesterone acetate therapy for young endometrial cancer patients.
Kitazawa S et al. J Gynecol Oncol. 2025
GeneralAdvanced/Recurrent2025
Modified posterior pelvic exenteration combined with ileocecal resection for locally advanced endometrial cancer.
Kato K et al. J Gynecol Oncol. 2025
MSI-H/dMMRAll Stages2025
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C et al. J Clin Oncol. 2025
ImmunotherapyAdvanced/Recurrent2025
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.
Nishio S et al. J Gynecol Oncol. 2025
GeneralAll Stages2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.
Harano K et al. J Gynecol Oncol. 2025
Hormone therapyAdvanced/Recurrent2025
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Mirza MR et al. Gynecol Oncol. 2025
GeneralAll Stages2025
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
Bae-Jump VL et al. Gynecol Oncol. 2025
GeneralAdvanced/Recurrent2025
Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines.
Hwang WY et al. J Gynecol Oncol. 2025
HER2+All Stages2025
HER2 expression in an endometrial cancer cohort.
Hacker KE et al. Gynecol Oncol. 2025
HER2+All Stages2025
HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
Cortés-Salgado A et al. Gynecol Oncol. 2025
Hormone therapyAll Stages2025
Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women.
Hadizadeh F et al. JAMA Oncol. 2025